Skip to main content
. 2020 Mar 24;7(3):844–855. doi: 10.1002/ehf2.12628

Table 2.

Baseline characteristics of the Doberman Pinschers of the treatment and control groups at enrolment (mean ± standard deviation or number and percentage)

Parameter Aptamer BC 007 Control 1 Control 2 P‐value C1 P‐value C2
Basic parameters
Gender (male/female) 8/6 (57%/43%) 7/7 (50%/50%) 9/5 (64%/36%) 0.705 0.699
Age (years) 7.2 ± 2.1 6.9 ± 2.3 7.3 ± 2.7 0.765 0.913
Weight (kg) 36.7 ± 6.5 37.2 ± 5.8 37.3 ± 5.0 0.824 0.784

β1‐AAB

(Δ beats/min)

21 ± 3 20 ± 6 0.400
Cardiac treatment
Pimobendan 13/14 (93%) 14/14 (100%) 14/14 (100%) 1.000 1.000
Ramipril 12/14 (86%) 12/14 (86%) 13/14 (93%) 1.000 1.000
Sotalol 5/14 (36%) 4/14/28%) 5/14 (36%) 1.000 1.000
Mexiletine 1/14 (7%) 0/14 (0%) 0/14 (0%) 1.000 1.000
Flecainide 5/14 (36%) 4/14 (28%) 2/14 (14%) 1.000 0.385
Amiodarone 2/14 (14%) 4/14 (28%) 4/14 (28%) 0.648 0.648
Furosemide 1/14 (7%) 0/14 (0%) 0/14 (0%) 1.000 1.000
Dogs treated with antiarrhythmics 7/14 (50%) 8/14 (57%) 9/14 (64%) 0.705 0.445
Time since start of pimobendan (months) 4.6 ± 4.9 3.3 ± 1.6 4.8 ± 2.0 0.352 0.854
Echocardiography
EDVI (mL/m2) 117 ± 33 108 ± 17 120 ± 33 0.349 0.814
ESVI (mL/m2) 81 ± 31 69 ± 16 80 ± 28 0.218 0.883
LA:Ao 1.36 ± 0.28 1.38 ± 0.09 1.36 ± 0.21 0.845 0.952
24 h Holter ECG
VPCs per 24 h 721 ± 1019 1821 ± 3159 503 ± 892 0.226 0.554
FR of VPCs (b.p.m.) 259 ± 36 270 ± 49 248 ± 42 0.510 0.455
VTach per 24 h 0.14 ± 0.54 2.21 ± 6.66 0.14 ± 0.54 0.256 1.000
Number of dogs with VTach 1/14 (7%) 3/14 (21%) 1/14 (7%) 0.596 1.000

Δ PR/min, change in pulse rate per minute; b.p.m., beats per minute; EDVI, end‐diastolic volume index; ESVI, end‐systolic volume index; FR, the fastest rate of all VPCs; LA:Ao, left atrial dimension to the aortic annulus dimension; VPCs, ventricular premature complexes; VTach, number of ventricular tachycardia.